Sridhar Mani, MD
Albert Einstein College of Medicine
11
5
10
N/A
0
15
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+11 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (11)
Showing 10 of 11 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Franco M. Muggia, MD
NYU Langone Health
Shared therapeutic areas:
Worked with same sponsors:
Pamela N. Munster, MD
Department of Medicine, University of California San Francisco
Shared therapeutic areas:
Worked with same sponsors:
Lin Shen, MD
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
lin shen
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Aminah Jatoi, MD
Mayo Clinic
Shared therapeutic areas:
Worked with same sponsors:
Mark Levine, MD
Ontario Clinical Oncology Group (OCOG)
Shared therapeutic areas:
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
Sabine Hazan, MD
ProgenaBiome
Shared therapeutic areas:
Areej El-Jawahri, MD
Massachusetts General Hospital
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (11)
Showing 11 of 11 trials
The Role of the Pregnane X Receptor (PXR) in Indole Signaling and Intestinal Permeability in Inflammatory Bowel Disease
Ixabepilone and Ketoconazole in Treating Patients With Advanced Solid Tumors
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer
Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin
Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors
Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer
All 11 trials loaded